Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment

European Respiratory Journal

Volumn 48, Issue 5, 2016, Pages 1369-1376

  Klok, Frederikus A ^a   Hösel, Volker ^b   Clemens, Andreas ^a   Yollo, Wilfrid D ^c   Tilke, Clemens ^d   Schulman, Sam ^e   Lankeit, Mareike ^a   Konstantinides, Stavros V ^a,f  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b StatSciConsult   (Germany)

^c Statistical Programming Pool (S2P)   (Cameroon)

^d Dr Tilke Consulting ^*  (Germany)

^e MCMASTER UNIVERSITY   (Canada)

^f DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; VENOUS THROMBOEMBOLISM; ADOLESCENT; AGED; ALGORITHM; DECISION MAKING; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL ANALYSIS; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; COHORT STUDIES; DABIGATRAN; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; FEMALE; HEMORRHAGE; HUMANS; MALE; MODELS, STATISTICAL; REGRESSION ANALYSIS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VENOUS THROMBOEMBOLISM; WARFARIN; YOUNG ADULT;

EID: 84994338117     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00280-2016     Document Type: Article

References (26)

1. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-3069.
2. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e419S-e494S.
3. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Thromb Haemost 2011; 106: 997-1011.
4. Klok FA, Kooiman J, Huisman MV, et al. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur Respir J 2015; 45: 201-210.
5. Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-460.
6. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
7. Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31.
8. Riva N, Bellesini M, Di Minno MN, et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost 2014; 112: 511-521.
9. Klok FA, Niemann C, Dellas C, et al. Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. J Thromb Thrombolysis 2016; 41: 312-320.
10. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
11. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011; 58: 395-401.
12. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719.
13. Kooiman J, van Hagen N, Iglesias Del Sol A, et al. The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLoS One 2015; 10: e0122520.
14. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e44S-e88S.
15. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772.
16. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
17. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
18. Kangelaris KN, Bent S, Nussbaum RL, et al. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009; 24: 656-664.
19. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114: 445S-469S.
20. Di Nisio M, Ageno W, Rutjes AW, et al. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost 2016; 115: 424-432.
21. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332.
22. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014; 63: 891-900.
23. Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121: 1630-1636.
24. Marcucci M, Iorio A, Douketis JD, et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. J Thromb Haemost 2015; 13: 775-781.
25. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417-426.
26. Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015; 350: g7594.